6. SGRQ class effects versus placebo (six months)a.
Effect vs placebo Class NWMA | Effect vs placebo Sensitivity analysis | Rank | ||||||
Class | Median | 95% CrI | Median | 95% CrI | Mean | Median | 95% CrI | Pr (best) |
LABA/ICS | ‐3.89 | (‐4.70 to ‐2.97) | ‐3.89 | (‐4.66 to ‐3.05) | 1.0 | 1 | (1 to 2) | 0.96 |
LAMA | ‐2.63 | (‐3.53 to ‐1.97) | ‐2.78 | (‐3.58 to ‐2.13) | 2.4 | 2 | (1 to 4) | 0.03 |
LABA | ‐2.29 | (‐3.18 to ‐1.53) | ‐2.09 | (‐2.93 to ‐1.36) | 3.1 | 3 | (2 to 4) | 0.01 |
ICS | ‐2.00 | (‐3.06 to ‐0.87) | ‐1.96 | (‐2.99 to ‐0.91) | 3.5 | 4 | (2 to 4) | 0.00 |
aFor effects versus placebo, smaller values indicate larger benefits of the active treatment; all doses are given in micrograms.
Crl = credible interval.
SGRQ = St George's Respiratory Questionnaire.
ICS = inhaled corticosteroid.
LABA = long‐acting beta2‐agonist.
LABA/ICS = long‐acting beta2‐agonist/inhaled corticosteroid.
LAMA = long‐acting antimuscarinic antagonist.
NWMA = network meta‐analysis.
Pr = probability.